[1]
|
Mehta, K., Gandhi, V., Pathak, S., Aggarwal, B.B. and Grover, R.K. (2014) Multi-Targeted Approach to Cancer Treatment: An International Translational Cancer Research Symposium. Anticancer Research, 34, 6791-6795.
|
[2]
|
Moffat, J.G., Rudolph, J. and Bailey, D. (2014) Phenotypic Screening in Cancer Drug Discovery—Past, Present and Future. Nature Reviews Drug Discovery, 13, 588-602.
http://dx.doi.org/10.1038/nrd4366
|
[3]
|
Adams, D.J. (2012) The Valley of Death in Anticancer Drug Development: A Reassessment. Trends in Pharmacological Sciences, 33, 173-180.
http://dx.doi.org/10.1016/j.tips.2012.02.001
|
[4]
|
Bailón-Moscoso, N., Romero-Benavides, J.C. and Ostrosky-Wegman, P. (2014) Development of Anticancer Drugs Based on the Hallmarks of Tumor Cells. Tumor Biology, 35, 3981-3995. http://dx.doi.org/10.1007/s13277-014-1649-y
|
[5]
|
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., et al. (2014) Review of Therapeutic Drug Monitoring of Anticancer Drugs Part Two—Targeted Therapies. European Journal of Cancer, 50, 2020-2036. http://dx.doi.org/10.1016/j.ejca.2014.04.015
|
[6]
|
Lim, S.H. and Levy, R. (2014) Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. The Journal of Immunology, 193, 1519-1524.
http://dx.doi.org/10.4049/jimmunol.1490027
|
[7]
|
Brown, C. (2016) Targeted Therapy: An Elusive Cancer Target. Nature, 537, S106-S108.
http://dx.doi.org/10.1038/537s106a
|
[8]
|
Zhou, L., Xu, N., Sun, Y. and Liu, X.M. (2014) Targeted Biopharmaceuticals for Cancer Treatment. Cancer Letters, 352, 145-151. http://dx.doi.org/10.1016/j.canlet.2014.06.020
|
[9]
|
Herviou, P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M., Eschalier, A., Durando, X. and Authier, N. (2016) Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors. Oncology Letters, 12, 1223-1232.
|
[10]
|
Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S.N, Shu, W., Shi, H., et al. (2015) Therapy-Induced Tumour Secretomes Promote Resistance and Tumour Progressio. Nature, 520, 368-372. http://dx.doi.org/10.1038/nature14336
|
[11]
|
Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H. and Ellis, H. (2015) Convergent Loss of PTEN Leads to Clinical Resistance to a PI(3)Kα Inhibitor. Nature, 518, 240-244.
http://dx.doi.org/10.1038/nature13948
|
[12]
|
Lieu, C.H., Tan, A.C., Leong, S., Diamond, J.R. and Eckhardt, S.G. (2013) From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 105, 1441-1456.
http://dx.doi.org/10.1093/jnci/djt209
|
[13]
|
Ryall, K.A. and Tan, A.C. (2015) Systems Biology Approaches for Advancing the Discovery Of Effective Drug Combinations. Journal of Cheminformatics, 7, 7.
http://dx.doi.org/10.1186/s13321-015-0055-9
|
[14]
|
Martz, C.A., Ottina, K.A., Singleton, K.R., Jasper, J.S., Wardell, S.E., Peraza-Penton, A., et al. (2014) Systematic Identification of Signaling Pathways with Potential to Confer Anticancer Drug Resistance. Science Signaling, 7, ra121.
http://dx.doi.org/10.1126/scisignal.aaa1877
|
[15]
|
Crystal, A.S., Shaw, A.T., Sequist, L.V., Friboulet, L., Niederst, M.J., Lockerman, E.L., et al. (2014) Patient-Derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer. Science, 346, 1480-1486. http://dx.doi.org/10.1126/science.1254721
|
[16]
|
Frangione, M.L., Lockhart, J.H., Morton, D.T., Pava, L.M. and Blanck, G. (2015) Anticipating Designer Drug-Resistant Cancer Cells. Drug Discovery Today, 20, 790-793.
http://dx.doi.org/10.1016/j.drudis.2015.02.005
|
[17]
|
Tong, L., Chuang, C.C., Wu, S. and Zuo, L. (2015) Reactive Oxygen Species in Redox Cancer Therapy. Cancer Letters, 367, 18-25. http://dx.doi.org/10.1016/j.canlet.2015.07.008
|
[18]
|
Yang, W., Zou, L., Huang, C. and Lei, Y. (2014) Redox Regulation of Cancer Metastasis: Molecular Signaling and Therapeutic Opportunities. Drug Development Research, 75, 331-341. http://dx.doi.org/10.1002/ddr.21216
|
[19]
|
Gad, H., Koolmeister, T., Jemth, A.S., Eshtad, S., Jacques, S.A. and Strom, C.E. (2014) MTH1 Inhibition Eradicates Cancer by Preventing Sanitation of the dNTP Pool. Nature, 508, 215-222 http://dx.doi.org/10.1038/nature13181
|
[20]
|
Kawagishi, H. and Finkel, T. (2014) Unraveling the Truth about Antioxidants: ROS and Disease: Finding the Right Balance. Nature Medicine, 20, 711-713.
http://dx.doi.org/10.1038/nm.3625
|
[21]
|
Sabharwal, S.S. and Schumacker, P.T. (2014) Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles’ Heel? Nature Reviews Cancer, 14, 709-721.
http://dx.doi.org/10.1038/nrc3803
|
[22]
|
Ristow, M. (2014) Unraveling the Truth about Antioxidants: Mitohormesis Explains ROS-Induced Health Benefits. Nature Medicine, 20, 709-711.
http://dx.doi.org/10.1038/nm.3624
|
[23]
|
Ibanez, I.L., Notcovich, C., Catalano, P.N., Bellino, M.G. and Durán, H. (2015) The Redox-Active Nanomaterial Toolbox for Cancer Therapy. Cancer Letters, 359, 9-19.
http://dx.doi.org/10.1016/j.canlet.2015.01.013
|
[24]
|
Lu, M., Lawrence, D.A., Marsters, S., Acosta-Alvear, D., Kimmig, P., Mendez, A.S., et al. (2014) Opposing Unfolded-Protein-Response Signals Converge on Death Receptor 5 to Control Apoptosis. Science, 345, 98-101. http://dx.doi.org/10.1126/science.1254312
|
[25]
|
Wang, M. and Kaufman, R.J. (2014) The Impact of the Endoplasmic Reticulum Protein-Folding Environment on Cancer Development. Nature Review Cancer, 14, 581-597.
http://dx.doi.org/10.1038/nrc3800
|
[26]
|
Hiramatsu, N., Chiang, W.C., Kurt, T.D., Sigurdson, C.J. and Lin, J.H. (2015) Multiple Mechanisms of Unfolded Protein Response-Induced Cell Death. American Journal of Pathology, 185, 1800-1808. http://dx.doi.org/10.1016/j.ajpath.2015.03.009
|
[27]
|
Maas, N.L. and Diehl, J.A. (2015) Molecular Pathways: The PERKs and Pitfalls of Targeting the Unfolded Protein Response in Cancer. Clinical Cancer Research, 21, 675-679.
http://dx.doi.org/10.1158/1078-0432.CCR-13-3239
|
[28]
|
Lee, A.S. (2014) Glucose-Regulated Proteins in Cancer: Molecular Mechanisms and Therapeutic Potential. Nature Review Cancer, 14, 263-276. http://dx.doi.org/10.1038/nrc3701
|
[29]
|
Tan, J.S., Ong, K.K.C. and Rhodes, A. (2016) The Role of Heat Shock Proteins and Glucose Regulated Proteins in Cancer. Malaysian Journal of Pathology, 38, 75-82.
|
[30]
|
Brüning, A. and Jückstock, J. (2015) Misfolded Proteins: From Little Villains to Little Helpers in the Fight against Cancer. Frontiers in Oncology, 5, 47.
|
[31]
|
Solárová, Z., Mojzis, J. and Solár, P. (2015) Hsp90 Inhibitor as a Sensitizer of Cancer Cells to Different Therapies. International Journal of Oncology, 46, 907-926.
|
[32]
|
Kukita, K., Tamura, Y., Tanaka, T., Kajiwara, T., Kutomi, G., Saito, K., et al. (2015) Cancer-Associated Oxidase ERO1-α Regulates the Expression of MHC Class I Molecule via Oxidative Folding. The Journal of Immunology, 194, 4988-4996.
http://dx.doi.org/10.4049/jimmunol.1303228
|
[33]
|
Tanaka, T., Kajiwara, T., Torigoe, T., Okamoto, Y., Sato, N. and Tamura, Y. (2015) Cancer-Associated Oxidoreductase ERO1-α Drives the Production of Tumor-Promoting Myeloid-Derived Suppressor Cells via Oxidative Protein Folding. The Journal of Immunology, 194, 2004-2010. http://dx.doi.org/10.4049/jimmunol.1402538
|
[34]
|
Delaunay-Moisan, A. and Appenzeller-Herzog, C. (2015) The Antioxidant Machinery of the Endoplasmic Reticulum: Protection and Signaling. Free Radical Biology & Medicine, 83, 341-351. http://dx.doi.org/10.1016/j.freeradbiomed.2015.02.019
|
[35]
|
Clarke, H.J., Chambers, J.E., Liniker, E. and Marciniak, S.J. (2014) Endoplasmic Reticulum Stress in Malignancy. Cancer Cell, 25, 563-573. http://dx.doi.org/10.1016/j.ccr.2014.03.015
|
[36]
|
Hu, Z.Y., Xiao, L., Bode, A.M., Dong, Z. and Cao, Y. (2014) Glycolytic Genes in Cancer Cells Are More than Glucose Metabolic Regulators. Journal of Molecular Medicine, 92, 837-845. http://dx.doi.org/10.1007/s00109-014-1174-x
|
[37]
|
Michels, J., Obrist, F., Castedo, M., Vitale, I. and Kroemer, G. (2014) PARP and Other Prospective Targets for Poisoning Cancer Cell Metabolism. Biochemical Pharmacology, 92, 164-171. http://dx.doi.org/10.1016/j.bcp.2014.08.026
|
[38]
|
Augoff, K., Hryniewicz-Jankowska, A. and Tabola, R. (2015) Lactate Dehydrogenase 5: An Old Friend and a New Hope in the War on Cancer. Cancer Letters, 358, 1-7.
http://dx.doi.org/10.1016/j.canlet.2014.12.035
|
[39]
|
Fiume, L., Manerba, M., Vettraino, M. and Di Stefano, G. (2014) Inhibition of Lactate Dehydrogenase Activity as an Approach to Cancer Therapy. Future Medicinal Chemistry, 6, 429-445. http://dx.doi.org/10.4155/fmc.13.206
|
[40]
|
Yélamos, J., Galindo, M., Navarro, J., Albanell, J., Rovira, A., Rojo, F. and Oliver, J. (2015) Enhancing Tumor-Targeting Monoclonal Antibodies Therapy by PARP Inhibitors. Oncoimmunology, 5, e1065370. http://dx.doi.org/10.1080/2162402X.2015.1065370
|
[41]
|
Rodríguez-Enríquez, S., Gallardo-Pérez, J.C., Hernández-Reséndiz, I., Marín-Hernández, A., Pacheco-Velázquez, S.C., López-Ramírez, S.Y., et al. (2014) Canonical and New Generation Anticancer Drugs Also Target Energy Metabolism. Archives of Toxicology, 88, 1327-1350. http://dx.doi.org/10.1007/s00204-014-1246-2
|
[42]
|
Bhat, T.A., Kumar, S., Chaudhary, A.K., Yadav, N. and Chandra, D. (2015) Restoration of Mitochondria Function as a Target for Cancer Therapy. Drug Discovery Today, 20, 635-643. http://dx.doi.org/10.1016/j.drudis.2015.03.001
|
[43]
|
Ji, D., Beharry, A.A., Ford, J.M. and Kool, E.T. (2016) A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. Journal of the American Chemical Society, 138, 9005-9008.
http://dx.doi.org/10.1021/jacs.6b02895
|
[44]
|
Huber, K.V., Salah, E., Radic, B., Gridling, M., Elkins, J.M., Stukalov, A., et al. (2014) Stereospecific Targeting of MTH1 by (S)-Crizotinib as an Anticancer Strategy. Nature, 508, 222-227. http://dx.doi.org/10.1038/nature13194
|
[45]
|
DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F. and Jacks, T. (2012) Expression of tumour-Specific Antigens Underlies Cancer Immunoediting. Nature, 482, 405-409.
http://dx.doi.org/10.1038/nature10803
|
[46]
|
Teng, M.W., Galon, J., Fridman, W.H. and Smyth, M.J. (2015) From Mice to Humans: Developments in Cancer Immunoediting. Journal of Clinical Investigation, 125, 3338-3346.
http://dx.doi.org/10.1172/JCI80004
|
[47]
|
Kareva, I. and Berezovskaya, F. (2015) Cancer Immunoediting: A Process Driven by Metabolic Competition as a Predator-Prey-Shared Resource Type Model. Journal of Theoretical Biology, 380, 463-472. http://dx.doi.org/10.1016/j.jtbi.2015.06.007
|
[48]
|
Makkouk, A. and Weiner, G.J. (2015) Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. Cancer Research, 75, 5-10.
http://dx.doi.org/10.1158/0008-5472.CAN-14-2538
|
[49]
|
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A., Galon, J., Sautès-Fridman, C., et al. (2014) Trial Watch: Toll-Like Receptor Agonists in Oncological Indications. Oncoimmunology, 3, e29179. http://dx.doi.org/10.4161/onci.29179
|
[50]
|
Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. http://dx.doi.org/10.1038/nature14011
|
[51]
|
Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautès-Fridman, C., Tartour, E., et al. (2013) Trial Watch: Peptide Vaccines in Cancer Therapy. Oncoimmunology, 2, e26621.
http://dx.doi.org/10.4161/onci.26621
|
[52]
|
Pauken, K.E. and Wherry, E.J. (2014) TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit. Cancer Cell, 26, 785-787. http://dx.doi.org/10.1016/j.ccell.2014.11.016
|
[53]
|
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., et al. (2014) Trial Watch: Tumor-Targeting Monoclonal Antibodies in Cancer Therapy. Oncoimmunology, 3, e27048. http://dx.doi.org/10.4161/onci.27048
|
[54]
|
Zheng, Y., Dou, Y., Duan, L., Cong, C., Gao, A., Lai, Q., et al. (2015) Using Chemo-Drugs or Irradiation to Break Immune Tolerance and Facilitate Immunotherapy in Solid Cancer. Cellular Immunology, 294, 54-59. http://dx.doi.org/10.1016/j.cellimm.2015.02.003
|
[55]
|
Gomez-Roca, C. and Delord, J.P. (2014) Emerging New Anticancer Therapies in 2013. Current Opinion in Oncology, 26, 357-362.
http://dx.doi.org/10.1097/CCO.0000000000000081
|
[56]
|
Ivanova, T.S., Krupodorova, T.A., Barshteyn, V.Y., Artamonova, A.B. and Shlyakhovenko, V.A. (2014) Anticancer Substances of Mushroom Origin. Experimental Oncology, 36, 58-66.
|
[57]
|
Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. (2014) MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. Nature, 515, 558-562. http://dx.doi.org/10.1038/nature13904
|
[58]
|
Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. (2014) PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature, 515, 568-571. http://dx.doi.org/10.1038/nature13954
|
[59]
|
Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A. and Wolchok, J.D. (2015) Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies. Annals of Oncology, 27, 1362. http://dx.doi.org/10.1093/annonc/mdw141
|
[60]
|
Hoffman, R.M. and Zhao, M. (2014) Methods for the Development of Tumor-Targeting Bacteria. Expert Opinion on Drug Discovery, 9, 741-750.
http://dx.doi.org/10.1517/17460441.2014.916270
|
[61]
|
Dhillon, S. (2015) Dinutuximab: First Global Approval. Drugs, 75, 923-927.
http://dx.doi.org/10.1007/s40265-015-0399-5
|
[62]
|
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61. http://dx.doi.org/10.1126/science.aaa8172
|
[63]
|
Shahabi, V., Postow, M.A., Tuck, D. and Wolchok, J.D. (2015) Immune-Priming of the Tumor Microenvironment by Radiotherapy: Rationale for Combination with Immunotherapy to Improve Anticancer Efficacy. American Journal of Clinical Oncology, 38, 90-97.
http://dx.doi.org/10.1097/COC.0b013e3182868ec8
|
[64]
|
André, N., Carré, M. and Pasquier, E. (2014) Metronomics: Towards Personalized Chemotherapy? Nature Reviews Clinical Oncology, 11, 413-431.
http://dx.doi.org/10.1038/nrclinonc.2014.89
|
[65]
|
Demaria, S., Pilones, K.A., Vanpouille-Box, C., Golden, E.B. and Formenti, S.C. (2014) The Optimal Partnership of Radiation and Immunotherapy: From Preclinical Studies to Clinical Translation. Radiation Research, 182, 170-181. http://dx.doi.org/10.1667/RR13500.1
|
[66]
|
Esposito, A., Criscitiello, C. and Curigliano, G. (2015) Immune Checkpoint Inhibitors with Radiotherapy and Locoregional Treatment: Synergism and Potential Clinical Implication. Current Opinion in Oncology, 27, 445-451.
http://dx.doi.org/10.1097/CCO.0000000000000225
|
[67]
|
Regal, J.F., Dornfeld, K.J. and Fleming, S.D. (2016) Radiotherapy: Killing with Complement. Annals of Translational Medicine, 4, 94. http://dx.doi.org/10.21037/atm.2015.12.46
|